NIH-funded 'systems biology' project aims to solve TB conundrum
This article was originally published in Scrip
With the effectiveness unpredictable of the current vaccine used to protect against tuberculosis – which is thought to have infected about a third of the world's population, although most of those cases are latent – and the therapies to treat the infection considered toxic, difficult to take and growing increasingly resistant, it's critical scientists gain a better understanding of the disease, said Dr David Sherman, a professor at Seattle Biomedical Research Institute.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.